Summary

The global market for Restriction Endonucleases was estimated to be worth US$ 302 million in 2024 and is forecast to a readjusted size of US$ 445 million by 2031 with a CAGR of 5.8% during the forecast period 2025-2031.

Restriction Endonuclease is an enzyme that cuts DNA at or near specific recognition nucleotide sequences known as restriction sites. They are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. Restriction enzymes are commonly classified into four types, which differ in their structure and whether they cut their DNA substrate at their recognition site, or if the recognition and cleavage sites are separate from one another.
The Restriction Endonuclease industry is relatively concentrated, and the players mainly come from North America and Western Europe. In the world wide, major manufactures mainly are New England Biolabs, Thermo Fisher Scientific, Takara Bio, Illumina, Agilent Technologies, Roche, GE Healthcare, Promega Corporation, Qiagen and Jena Biosciences, etc, with about 88% market shares.
This report aims to provide a comprehensive presentation of the global market for Restriction Endonucleases, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Restriction Endonucleases by region & country, by Type, and by Application.

The Restriction Endonucleases market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Restriction Endonucleases.

Market Segmentation
By Company
New England Biolabs
Thermo Fisher Scientific
Takara Bio
Illumina
Agilent
Roche
GE Healthcare
Promega
Qiagen
Jena Biosciences
Segment by Type
Type I
Type II
Type III
Type IV
Others
Segment by Application
Academic & Research Institutes
Hospitals & Diagnostic Centers
Biopharmaceutical
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Restriction Endonucleases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Restriction Endonucleases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Restriction Endonucleases in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Restriction Endonucleases Product Introduction
1.2 Global Restriction Endonucleases Market Size Forecast
1.2.1 Global Restriction Endonucleases Sales Value (2020-2031)
1.2.2 Global Restriction Endonucleases Sales Volume (2020-2031)
1.2.3 Global Restriction Endonucleases Sales Price (2020-2031)
1.3 Restriction Endonucleases Market Trends & Drivers
1.3.1 Restriction Endonucleases Industry Trends
1.3.2 Restriction Endonucleases Market Drivers & Opportunity
1.3.3 Restriction Endonucleases Market Challenges
1.3.4 Restriction Endonucleases Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Restriction Endonucleases Players Revenue Ranking (2024)
2.2 Global Restriction Endonucleases Revenue by Company (2020-2025)
2.3 Global Restriction Endonucleases Players Sales Volume Ranking (2024)
2.4 Global Restriction Endonucleases Sales Volume by Company Players (2020-2025)
2.5 Global Restriction Endonucleases Average Price by Company (2020-2025)
2.6 Key Manufacturers Restriction Endonucleases Manufacturing Base and Headquarters
2.7 Key Manufacturers Restriction Endonucleases Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Restriction Endonucleases
2.9 Restriction Endonucleases Market Competitive Analysis
2.9.1 Restriction Endonucleases Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Restriction Endonucleases Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Restriction Endonucleases as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Type I
3.1.2 Type II
3.1.3 Type III
3.1.4 Type IV
3.1.5 Others
3.2 Global Restriction Endonucleases Sales Value by Type
3.2.1 Global Restriction Endonucleases Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Restriction Endonucleases Sales Value, by Type (2020-2031)
3.2.3 Global Restriction Endonucleases Sales Value, by Type (%) (2020-2031)
3.3 Global Restriction Endonucleases Sales Volume by Type
3.3.1 Global Restriction Endonucleases Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Restriction Endonucleases Sales Volume, by Type (2020-2031)
3.3.3 Global Restriction Endonucleases Sales Volume, by Type (%) (2020-2031)
3.4 Global Restriction Endonucleases Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Academic & Research Institutes
4.1.2 Hospitals & Diagnostic Centers
4.1.3 Biopharmaceutical
4.1.4 Others
4.2 Global Restriction Endonucleases Sales Value by Application
4.2.1 Global Restriction Endonucleases Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Restriction Endonucleases Sales Value, by Application (2020-2031)
4.2.3 Global Restriction Endonucleases Sales Value, by Application (%) (2020-2031)
4.3 Global Restriction Endonucleases Sales Volume by Application
4.3.1 Global Restriction Endonucleases Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Restriction Endonucleases Sales Volume, by Application (2020-2031)
4.3.3 Global Restriction Endonucleases Sales Volume, by Application (%) (2020-2031)
4.4 Global Restriction Endonucleases Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Restriction Endonucleases Sales Value by Region
5.1.1 Global Restriction Endonucleases Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Restriction Endonucleases Sales Value by Region (2020-2025)
5.1.3 Global Restriction Endonucleases Sales Value by Region (2026-2031)
5.1.4 Global Restriction Endonucleases Sales Value by Region (%), (2020-2031)
5.2 Global Restriction Endonucleases Sales Volume by Region
5.2.1 Global Restriction Endonucleases Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Restriction Endonucleases Sales Volume by Region (2020-2025)
5.2.3 Global Restriction Endonucleases Sales Volume by Region (2026-2031)
5.2.4 Global Restriction Endonucleases Sales Volume by Region (%), (2020-2031)
5.3 Global Restriction Endonucleases Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Restriction Endonucleases Sales Value, 2020-2031
5.4.2 North America Restriction Endonucleases Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Restriction Endonucleases Sales Value, 2020-2031
5.5.2 Europe Restriction Endonucleases Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Restriction Endonucleases Sales Value, 2020-2031
5.6.2 Asia Pacific Restriction Endonucleases Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Restriction Endonucleases Sales Value, 2020-2031
5.7.2 South America Restriction Endonucleases Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Restriction Endonucleases Sales Value, 2020-2031
5.8.2 Middle East & Africa Restriction Endonucleases Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Restriction Endonucleases Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Restriction Endonucleases Sales Value
6.2.1 Key Countries/Regions Restriction Endonucleases Sales Value, 2020-2031
6.2.2 Key Countries/Regions Restriction Endonucleases Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Restriction Endonucleases Sales Value, 2020-2031
6.3.2 United States Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Restriction Endonucleases Sales Value, 2020-2031
6.4.2 Europe Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Restriction Endonucleases Sales Value, 2020-2031
6.5.2 China Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.5.3 China Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Restriction Endonucleases Sales Value, 2020-2031
6.6.2 Japan Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Restriction Endonucleases Sales Value, 2020-2031
6.7.2 South Korea Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Restriction Endonucleases Sales Value, 2020-2031
6.8.2 Southeast Asia Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Restriction Endonucleases Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Restriction Endonucleases Sales Value, 2020-2031
6.9.2 India Restriction Endonucleases Sales Value by Type (%), 2024 VS 2031
6.9.3 India Restriction Endonucleases Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 New England Biolabs
7.1.1 New England Biolabs Company Information
7.1.2 New England Biolabs Introduction and Business Overview
7.1.3 New England Biolabs Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 New England Biolabs Restriction Endonucleases Product Offerings
7.1.5 New England Biolabs Recent Development
7.2 Thermo Fisher Scientific
7.2.1 Thermo Fisher Scientific Company Information
7.2.2 Thermo Fisher Scientific Introduction and Business Overview
7.2.3 Thermo Fisher Scientific Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Thermo Fisher Scientific Restriction Endonucleases Product Offerings
7.2.5 Thermo Fisher Scientific Recent Development
7.3 Takara Bio
7.3.1 Takara Bio Company Information
7.3.2 Takara Bio Introduction and Business Overview
7.3.3 Takara Bio Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Takara Bio Restriction Endonucleases Product Offerings
7.3.5 Takara Bio Recent Development
7.4 Illumina
7.4.1 Illumina Company Information
7.4.2 Illumina Introduction and Business Overview
7.4.3 Illumina Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Illumina Restriction Endonucleases Product Offerings
7.4.5 Illumina Recent Development
7.5 Agilent
7.5.1 Agilent Company Information
7.5.2 Agilent Introduction and Business Overview
7.5.3 Agilent Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Agilent Restriction Endonucleases Product Offerings
7.5.5 Agilent Recent Development
7.6 Roche
7.6.1 Roche Company Information
7.6.2 Roche Introduction and Business Overview
7.6.3 Roche Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Roche Restriction Endonucleases Product Offerings
7.6.5 Roche Recent Development
7.7 GE Healthcare
7.7.1 GE Healthcare Company Information
7.7.2 GE Healthcare Introduction and Business Overview
7.7.3 GE Healthcare Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 GE Healthcare Restriction Endonucleases Product Offerings
7.7.5 GE Healthcare Recent Development
7.8 Promega
7.8.1 Promega Company Information
7.8.2 Promega Introduction and Business Overview
7.8.3 Promega Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Promega Restriction Endonucleases Product Offerings
7.8.5 Promega Recent Development
7.9 Qiagen
7.9.1 Qiagen Company Information
7.9.2 Qiagen Introduction and Business Overview
7.9.3 Qiagen Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Qiagen Restriction Endonucleases Product Offerings
7.9.5 Qiagen Recent Development
7.10 Jena Biosciences
7.10.1 Jena Biosciences Company Information
7.10.2 Jena Biosciences Introduction and Business Overview
7.10.3 Jena Biosciences Restriction Endonucleases Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Jena Biosciences Restriction Endonucleases Product Offerings
7.10.5 Jena Biosciences Recent Development
8 Industry Chain Analysis
8.1 Restriction Endonucleases Industrial Chain
8.2 Restriction Endonucleases Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Restriction Endonucleases Sales Model
8.5.2 Sales Channel
8.5.3 Restriction Endonucleases Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer